Diamond-Blackfan anemia

Article written and reviewed by Dr Luca Moretti

Diamond-Blackfan anemia is a rare congenital hematologic syndrome belonging to the group of ribosomopathies and characterized by selective failure of the erythroid lineage in the bone marrow. It typically presents with severe macrocytic or normocytic anemia of early onset, often during the first months of life, associated with marked reticulocytopenia and, in most cases, preservation of the other hematopoietic cell lineages. A distinctive feature of the disease is the absence of signs of hemolysis or increased peripheral red blood cell destruction despite profoundly impaired erythroid production.

Clinically, Diamond-Blackfan anemia is frequently accompanied by congenital malformations of varying severity that may involve the craniofacial region, extremities, heart, and urogenital system. Affected patients also have a documented increased risk of malignancies, both hematologic and solid, over their lifetime. In recent years, advances in the understanding of genetic and molecular mechanisms have established Diamond-Blackfan anemia as a paradigm of ribosomopathies, diseases caused by alterations in genes encoding ribosomal proteins, with a selective impact on erythroid maturation and multisystem consequences.

The most recent international nosology uses the term DBA syndrome, which encompasses a broader phenotypic spectrum than classic anemia alone and may include individuals with compatible genetic or syndromic features even in the absence of overt anemia.

Etiology and risk factors

Diamond-Blackfan anemia is caused by germline mutations that mainly affect genes encoding ribosomal proteins, but also nonribosomal genes associated with the syndrome, such as GATA1, TSR2, and HEATR3; rare forms associated with germline gain-of-function variants of TP53 have also been described. Inheritance is most often autosomal dominant, but X linked and autosomal recessive forms have also been described; many variants arise de novo. The most frequently involved gene is RPS19, mutations of which account for approximately one quarter of all diagnosed cases. In addition to RPS19, numerous other mutations have been described in genes such as RPL5, RPL11, RPS24, RPS17, and others, contributing to a heterogeneous genetic landscape.

Mutations involving RPL5 and RPL11 are particularly relevant because of their association with more pronounced congenital malformations, especially craniofacial and skeletal abnormalities and cardiac defects. However, approximately 20-30% of patients have no known mutation among the genes identified to date, suggesting possible involvement of other ribosomal genes that remain to be discovered or different pathogenic mechanisms that have not yet been fully clarified.

Disease expressivity can vary widely even among individuals within the same family, ranging from severe anemia during the first months of life to milder, late onset, or even oligosymptomatic presentations. This variability is attributable both to the specific type of mutation and to modifying genetic factors and environmental interactions that remain partly unknown.

In the great majority of cases, Diamond-Blackfan anemia develops as a direct consequence of the genetic mutation, without acquired causes or environmental factors capable of inducing the disease in healthy individuals. However, some risk factors may modulate the severity of the clinical presentation in patients who already carry the mutation. These include intercurrent viral infections, such as parvovirus B19, metabolic stress, surgical procedures, and other conditions that increase erythropoietic demand, which may precipitate acute anemic crises or worsen reticulocytopenia.

It is important to emphasize that these factors are not primary causes of the disorder but may worsen the clinical picture in genetically predisposed individuals. In some cases, anemia may appear transiently attenuated or exacerbated in relation to intercurrent events, contributing to variability in the natural history of the disease.

Pathogenesis and pathophysiology

In most cases, the pathogenesis of Diamond-Blackfan anemia is related to the effect of ribosomal gene mutations on hematopoietic stem cell biology, particularly on erythroid precursors. Defective synthesis or assembly of ribosomal proteins causes reduced ribosome biogenesis capacity and profound disruption of cellular protein synthesis. This imbalance particularly affects erythroblastic cells, whose rapid turnover and intense transcriptional activity make the erythroid lineage especially vulnerable to functional ribosome depletion. In forms caused by nonribosomal genes, erythroid failure results from different mechanisms.

In forms caused by ribosomal defects, the central pathogenic mechanism is activation of cellular response pathways to ribosomal injury. Ribosomal protein deficiency causes accumulation of incomplete or malformed ribosomal subunits, which in turn produces a state of ribosomal stress capable of activating the p53 pathway, the main regulator of the cellular response to genomic and cellular damage. Hyperactivation of p53 causes cell cycle arrest and selective apoptosis of erythroid progenitors, with progressive loss of the capacity for differentiation and maturation of red cell lineage cells.

Unlike other forms of bone marrow failure, the lesion in Diamond-Blackfan anemia is almost entirely restricted to the erythroid lineage: the bone marrow appears normocellular or only mildly hypocellular but has marked depletion of erythroid precursors, whereas the granulocytic and megakaryocytic lineages are initially preserved. The peripheral blood smear shows marked anemia with severe reticulocytopenia but no signs of hemolysis or the ineffective hematopoiesis typical of thalassemias or myelodysplastic syndromes.

A distinctive pathophysiologic feature of Diamond-Blackfan anemia is a compensatory increase in endogenous erythropoietin levels in response to chronic anemia. This increase, however, is ineffective because erythroid progenitors cannot respond adequately to the proliferative stimulus due to the underlying ribosomal defect.

Ribosomal dysfunction is associated with congenital malformations and an intrinsic predisposition to hematologic and solid malignancies. The mechanisms underlying cancer predisposition are complex and not completely defined; it cannot be attributed, as a demonstrated mechanism, to generic genomic instability induced by the ribosomal defect.

Taken together, these mechanisms generate the typical picture of Diamond-Blackfan anemia: chronic macrocytic or normocytic anemia with reticulocytopenia, without overt pancytopenia, often associated with congenital malformations and, over the long term, a significantly increased risk of malignancy. The severity of the clinical presentation and disease progression depend on the extent of the ribosomal defect, the specific mutation, and modifying factors that have not yet been fully elucidated.

Clinical presentation

The onset and clinical evolution of Diamond-Blackfan anemia are highly heterogeneous, reflecting variability in mutations and expression of the ribosomal defect. In most cases, the disease presents during the first months of life, often within the first year, with symptoms attributable to chronic and progressive anemia. The classic clinical presentation includes cutaneous and mucosal pallor of varying severity, progressive fatigue, poor growth, and reduced exercise tolerance even in neonates and infants. Onset may be insidious and sometimes unrecognized, particularly in less severe or partially compensated forms.

A typical feature is profound reticulocytopenia, which contributes to the severity of anemia and is accompanied by clinical signs of tissue hypoxia such as tachycardia, dyspnea, and, in more severe cases, high output heart failure with congestion and profuse sweating. In infants, height and weight growth delay and poor vitality may prompt diagnostic evaluation. Unlike other forms of chronic anemia, jaundice, signs of hemolysis, and bleeding manifestations are generally absent in Diamond-Blackfan anemia, while recurrent infections and spontaneous bleeding are uncommon because the other bone marrow lineages are relatively preserved.

In approximately 40-50% of patients, the disease is associated with congenital malformations. The most common defects involve the craniofacial region, thumbs and upper limbs, heart, urogenital system, and growth. Abnormalities may be minimal or absent, or they may affect prognosis and quality of life.

On physical examination, in addition to cutaneous and mucosal pallor, functional systolic murmurs related to anemia may be detected, sometimes together with tachycardia and mild signs of heart failure in more severe cases. Lymphadenopathy, significant hepatosplenomegaly, and signs of bone marrow infiltration are generally absent, distinguishing Diamond-Blackfan anemia from other pediatric hematologic disorders.

In rarer cases, particularly at older ages or in the presence of aggravating factors, signs of broader bone marrow failure with leukopenia or thrombocytopenia may emerge, but this is an exception to the classic course. A clinically important feature is the tendency, in a minority of patients, toward partial or complete spontaneous remissions, often temporary and followed by relapses even many years later.

The history must always investigate similar cases in the family, episodes of severe anemia in childhood, associated malformations, and a history of malignancy, all of which are essential both for differential diagnosis and for long term risk assessment.

Diagnostic evaluation and diagnosis

The diagnostic workup for Diamond-Blackfan anemia is based on a rigorous clinical and laboratory assessment capable of recognizing the characteristic presentation and excluding all possible alternative diagnoses of hyporegenerative anemia in childhood. The first finding that must raise suspicion is early onset macrocytic or normocytic anemia, often during the first six to twelve months of life, accompanied by marked reticulocytopenia and the absence of signs of hemolysis or deficits in the other cell lineages. A careful medical history and physical examination, with particular attention to congenital malformations, are crucial for directing the diagnostic pathway correctly.

The first laboratory step is a complete blood count, which documents an isolated reduction in hemoglobin concentration, increased or normal mean corpuscular volume, and a reduced reticulocyte count. The other hematopoietic lineages are usually preserved, at least during the initial phase of the disease. The peripheral blood smear shows normocytic or macrocytic erythrocytes without significant anisopoikilocytosis or dysplastic elements and with no schistocytes or spherocytes.

Useful initial and supportive diagnostic tests also include erythrocyte adenosine deaminase activity (eADA) and quantification of HbF, which should be interpreted together with the clinical, hematologic, and genetic findings.

When clinical suspicion is well founded, bone marrow examination is performed and is essential for confirming the selective erythroid lineage deficit. Bone marrow aspiration and biopsy usually show normocellular or only mildly hypocellular marrow, with marked reduction or absence of mature erythroblasts, while the granulocytic and megakaryocytic lineages are preserved. The presence of only a small number of immature erythroid cells without neoplastic infiltration, fibrosis, or dysplasia is highly suggestive of the diagnosis.

The differential diagnosis requires exclusion of all other causes of hyporegenerative anemia in childhood, such as transient erythroid aplasia, for example due to parvovirus B19, pediatric myelodysplastic syndromes, severe nutritional deficiency states involving vitamin B12 or folate, Fanconi anemia, and other congenital bone marrow failure syndromes. In this workup, vitamin measurements, liver and renal function tests, hemolysis markers, and testing for recent infections that can mimic the disorder are essential.

Recognition of associated congenital malformations, including craniofacial defects, limb malformations, cardiac abnormalities, or urogenital anomalies, is very helpful in directing the diagnosis toward Diamond-Blackfan anemia, especially when the hematologic picture is subtle. A positive family history of childhood anemia, similar malformations, or malignancies strengthens diagnostic suspicion and may prompt genetic counseling.

Molecular genetic analysis can confirm the diagnosis through identification of a pathogenic variant in one of the genes associated with the syndrome, including ribosomal protein genes and nonribosomal genes such as GATA1, TSR2, and HEATR3, as well as rare germline gain-of-function variants of TP53. Genetic screening is recommended in all suspected cases regardless of family history because many variants arise de novo. A negative genetic result does not exclude the diagnosis, which can be established on the basis of clinical and laboratory findings and exclusion of alternative diagnoses.

Additional investigations useful for further characterizing the disease and stratifying risk include assessment of cardiac and renal function to identify associated malformations, echocardiography, renal ultrasonography, and, in more complex cases, further hematologic evaluation by flow cytometry or cytogenetic analysis. Careful clinical and laboratory monitoring over time is essential to evaluate disease course, response to treatment, and the development of possible complications, such as progression to myelodysplastic syndromes or the appearance of malignancies.

Treatment and prognosis

Treatment of Diamond-Blackfan anemia is a clinical challenge that requires an individualized strategy based on patient age, anemia severity, associated malformations, and comorbidities. The primary goal is to ensure adequate tissue oxygenation, prevent complications related to severe chronic anemia, and minimize adverse effects of therapies in both the short and long term.

After the first year of life, corticosteroids may be used in symptomatic children; in infants, transfusion support is initially preferred to limit steroid toxicity. A substantial proportion of patients respond initially, but the dose must be reduced to the lowest effective level and continuation depends on efficacy and toxicity. Adverse effects include growth impairment, osteoporosis, hypertension, immunosuppression, and metabolic abnormalities.

The initial trial with prednisone or prednisolone generally uses 2 mg/kg/day, up to a maximum of 80 mg/day, and should not continue beyond 4 weeks without an adequate response. After a response, the dose should be reduced; a maintenance dose above 0.3 mg/kg/day required to maintain Hb ≥9 g/dL identifies a response that is not sustainable because of long term toxicity.

In patients who do not respond to corticosteroids, develop intolerable adverse effects, or lose response over time, regular packed red blood cell transfusions become necessary to maintain adequate hemoglobin levels. The transfusion program generally aims for a pretransfusion Hb of at least 9 to 10 g/dL, regardless of age, with the target individualized upward when necessary to keep the patient asymptomatic. This approach provides good symptom control but exposes patients to the risk of iron overload, with progressive iron accumulation in vital organs. For this reason, iron chelation must be started when monitoring documents clinically significant iron overload, to prevent hepatic, cardiac, and endocrine damage. In transfused patients, current consensus recommends an early and aggressive approach to iron chelation and quantification of iron burden, including magnetic resonance imaging of hepatic and cardiac iron when indicated.

Allogeneic hematopoietic stem cell transplantation can correct the hematologic phenotype and is considered in selected patients with transfusion dependence or severe toxicity or ineffectiveness of conventional therapy. Outcomes depend strongly on age, donor, compatibility, iron overload, and comorbidities; applying a single survival percentage to all settings is inappropriate.

In transfusion dependent children, either a matched family donor or a 10/10 matched unrelated donor may be used. When transplantation is indicated, outcomes generally favor performing it before 10 years of age and, when possible, during the preschool years.

Strategies targeting ribosomal stress, p53, and genetic correction are under investigation. Erythropoiesis stimulating agents are not effective routine therapy. Molecular approaches remain experimental and are not currently approved therapies for DBA.

The prognosis of Diamond-Blackfan anemia has improved significantly in recent decades because of advances in supportive therapy and transplantation protocols. However, long term survival depends on multiple factors, including response to treatment, corticosteroid tolerance, cumulative transfusion burden, and the presence of major malformations or organ complications. The main adverse prognostic factors are transfusion dependence, iron overload, treatment related complications, and the development of malignancies, which are among the leading causes of mortality in adulthood.

Multidisciplinary hematologic follow-up is essential for monitoring bone marrow function, treatment tolerance, growth and development, organ function, and the onset of complications over time, with particular attention to prevention and prompt treatment of iron overload and early diagnosis of associated malignancies. Therapeutic decisions must always be individualized and shared with the patient and family, with the aim of maximizing quality of life and minimizing long term risks.

Cancer surveillance includes colorectal screening beginning at age 20 years; if the first examination is normal, screening should generally be repeated every 5 years, unless shorter intervals are indicated.

Complications

Complications of Diamond-Blackfan anemia are a central component of clinical management because they profoundly affect both prognosis and patients' quality of life. These complications result from the chronic deficit in erythroid production, the long term effects of replacement and immunosuppressive therapies, and the intrinsic predisposition associated with ribosomal dysfunction.

During the initial phase, severe anemia may cause hypoxia, reduced exercise tolerance, and, rarely, high output heart failure. Severe and prolonged anemia that is not adequately treated may interfere with growth and development, but neurocognitive difficulties are not a specific intrinsic manifestation of DBA.

Iron overload is one of the major problems in transfusion dependent patients. Progressive iron accumulation, in the absence of a physiologic elimination pathway, causes hepatic siderosis, cardiomyopathy, endocrine dysfunction, including hypogonadism, diabetes mellitus, and hypothyroidism, and, in the most severe cases, organ failure. Iron toxicity requires regular, monitored chelation therapy, whose impact on quality of life and treatment adherence may be substantial.

Although often effective in inducing an erythropoietic response, corticosteroids are associated with metabolic and systemic complications such as growth arrest, osteoporosis, hypertension, immunosuppression, mood changes, and diabetes. In young children, the duration of steroid therapy must be constantly balanced against the risks of long term harm, which is why many patients require alternative strategies after the first years of life.

Although allogeneic hematopoietic stem cell transplantation can definitively correct the hematologic phenotype, it does not eliminate congenital malformations or cancer predisposition and carries risks of graft rejection, graft versus host disease (GVHD), opportunistic infections, conditioning chemotherapy toxicity, and, in patients with organ malformations, an increased risk of perioperative complications. Careful candidate selection and specialist follow-up are essential to minimize transplant related mortality.

One of the most feared complications is the predisposition to malignancies, both hematologic and solid. The risk is intrinsic to the syndrome, but the biological mechanisms are multifactorial and incompletely defined; it should not be described as the demonstrated consequence of generic genomic instability.

Other possible complications include congenital organ malformations that may affect prognosis independently of the hematologic disorder, infectious complications related to immunosuppression, particularly with prolonged steroid therapy or after transplantation, and psychological and social problems related to chronic disease and treatment burden.

Effective management of the complications of Diamond-Blackfan anemia requires a multidisciplinary approach and proactive, continuous monitoring aimed at prevention, prompt treatment of adverse events, and promotion of the best possible long term quality of life.

Bibliography
1. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009;23(2):261–282.
2. Wlodarski MW, Vlachos A, Farrar JE, et al. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. Lancet Haematol. 2024;11(5):e368–e382.
3. Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. Blood. 2020;136(11):1262–1273.
4. Ellis SR, Gleizes PE. Diamond Blackfan anemia: ribosomal proteins going rogue. Semin Hematol. 2011;48(2):89–96.
5. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142(6):859–876.
6. Campagnoli MF, Garelli E, Quarello P, et al. Molecular basis of Diamond-Blackfan anemia: new findings from the Italian registry and a review of the literature. Haematologica. 2004;89(4):480–489.
7. Alter BP. Inherited bone marrow failure syndromes: considerations pre- and posttransplant. Blood. 2017;130(21):2257–2264.
8. Vlachos A, Rosenberg PS, Atsidaftos E, et al. Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood. 2012;119(16):3815–3819.
9. Kaushansky K, et al. Williams Hematology. McGraw-Hill. 10th ed. 2021.
10. Greer JP, et al. Wintrobe’s Clinical Hematology. Wolters Kluwer. 14th ed. 2019.
11. Quarello P, Garelli E, Carando A, et al. Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica. 2010;95(2):206–213.